Lucid Diagnostics Stock
Lucid Diagnostics Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Lishan Aklog
- Employees
- 82
- Market cap
- $91 M
- IPO
- 14/10/2021
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing…
Lucid Diagnostics stock: price history
1D
-8.1%
1W
-25.1%
1M
-42.9%
6M
-61.8%
YTD
-56.1%
1Y
-61.1%
2Y
-41.0%
5Y
-94.9%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~17% stronger price swings than usual
Ask the agents about Lucid Diagnostics
Analyst assessment of Lucid Diagnostics
PRICE TARGET LOW
US$2.00
CONSENSUS
US$2.00
MEDIAN
US$2.00
PRICE TARGET HIGH
US$2.00
0
STRONG BUY
6
BUY
0
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 27/08/2026
Lucid Diagnostics stock metrics
P/E
-1.03
P/B
8.01
EV/EBITDA
-1.61
RETURN ON EQUITY
-107.0%
NET MARGIN
-792.9%
DEBT/EQUITY
2.28
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
73.7%
FLOAT SHARES
140,761,675
AVG. DAILY VOLUME (30D)
1,710,825
Insider transactions (SEC)
Matheis Dennis
Institutional holders
Comparable stocks
Frequently asked questions about Lucid Diagnostics stock
What does Lucid Diagnostics do?
Lucid Diagnostics Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Lishan Aklog, the company employs around 82 people.
The IPO was on 14/10/2021; the stock trades on NASDAQ under the ticker LUCD.
What do analysts say about Lucid Diagnostics stock?
6 analysts rate the stock, the consensus is Buy (as of 27/08/2026).
The average price target is US$2.00, ranging from US$2.00 to US$2.00, with a median of US$2.00.
This is an external assessment, not a statement by Market Jury.
When does Lucid Diagnostics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 17% stronger than usual.
Does Lucid Diagnostics pay a dividend?
No, Lucid Diagnostics currently does not pay a dividend.
Which stocks are comparable to Lucid Diagnostics?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Lucid Diagnostics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Lucid Diagnostics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.